NCT03278483View on ClinicalTrials.gov

Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL)

PHASE4CompletedINTERVENTIONAL
Enrollment

396

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Diabetes MellitusTuberculin (Skin Test) Positive
Interventions
DRUG

Isoniazid 300 mg Oral Tablet

Isoniazid tablets 300mg daily plus pyridoxine 50mg daily

DRUG

Rifampin 600 mg Oral Tablet

Rifampin capsules 600mg daily

Trial Locations (1)

14000

Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City

All Listed Sponsors
collaborator

Instituto Nacional de Enfermedades Respiratorias

OTHER_GOV

collaborator

Instituto Nacional de Ciencias Medicas y Nutrición

UNKNOWN

lead

Instituto Nacional de Salud Publica, Mexico

OTHER

NCT03278483 - Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL) | Biotech Hunter | Biotech Hunter